Compare Heron Therapeutics Inc (HRTX) vs Lennar Corporation (LEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Lennar Corporation — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Lennar Corporation trades at $75.98 (market cap $18.44B). The key difference: Lennar Corporation is far larger — about 271.1× Heron Therapeutics Inc's market cap, and Lennar Corporation pays a 2.58% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Lennar Corporation for 67 Days on average.
| HRTX | LEN | |
|---|---|---|
Market Cap | $68.01M | $18.44B |
Volume | 1,891,941 | 6,012,214 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $133.13 |
52-Week Low | $0.27 | $74.44 |
Typical Hold Time | 35 Days | 67 Days |
Enterprise Value | $174.75M | $22.86B |
Dividend Yield | — | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Lennar Corporation (LEN) trades at $76.13, down 1.65% on the day, with a bearish technical outlook despite appearing fundamentally undervalued with a P/E of 14.7 and P/B of 0.86. Recent earnings have missed expectations for three consecutive quarters, with Q3 2026 results pending. Revenue declined to $34.19 billion in 2025 with net income falling to $2.08 billion, though Berkshire Hathaway has significantly increased its stake, now owning over 11% of the homebuilder.
The stock presents a value opportunity given its below-book valuation and strong institutional backing, but faces headwinds from rising mortgage rates, weak housing sentiment, and recent allegations regarding sales practices. Analyst consensus is mixed with a $77.38 price target slightly above current levels, though technical indicators suggest near-term pressure with support at $74-75.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
